Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label attachment file name title
tabling member	label

Search

100186

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patients: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	211233
	answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>Missed or inadequate hydrocortisone administration is not currently included in the list of ‘never events’.</p><p> </p><p> </p><p> </p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 15:28:25 question first ministerially corrected 28/10/2014 16:30:53 answering member 4020 label Biography information for George Freeman previous answer version 24770 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
	tabling member	95 label Biography information for Mr Andrew Smith

100721

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211732
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100723

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Motor Neurone Disease: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211734
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100728

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Motor Neurone Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211730
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100730

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211735
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100885

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211885
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:29 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100887

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211918
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

105978

	registered interest
	date	03/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pay
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many Instant Rewards of what value were given to his Department's officials in (a) 2013 and (b) 2014 to date.
	tabling member constituency	Barrow and Furness
	tabling member printed	John Woodcock
	uin	213068
	answer	answer is ministerial correction date of answer 10/11/2014 answer text <p><del class="ministerial">The Civil Service Commission publish details of appointments made by exception and approved by them in their annual reports and on their website. These reports are available in the Library.</del></p><p><br /><del class="ministerial">It would not be appropriate to publish details of the requests turned down by the Commission as the numbers involved are small, and the individuals might be personally identified, directly or in combination with other published information.</del></p><p> </p><p><ins class="ministerial">The Department does not operate an ‘Instant Rewards’ scheme. The Department does, however, operate an in-year bonus scheme, which has strict criteria, approval processes and budgetary control.</ins></p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 10/11/2014 16:58:06 question first ministerially corrected 10/11/2014 17:38:55 answering member 3932 label Biography information for Dr Dan Poulter previous answer version 27280 answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	3917 label Biography information for Lord Walney

164499

	registered interest
	date	24/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Negligence
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government by how much the provision for clinical negligence claims against the National Health Service has grown in the last year; why it has grown; and what strategy is in place for reducing that amount.
	tabling member printed	Lord Sharkey
	uin	HL3092
	answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>As at 31 March 2014, the National Health Service Litigation Authority (NHS LA) estimates that it has potential liabilities of £26.1 billion, of which £25.7 billion relates to clinical negligence. This is an increase of £3.1 billion from 31 March 201<del class="ministerial">4<ins class="ministerial">3</ins></del>, which can mainly be attributed to a continual rise in clinical negligence claims over recent years. There are a number of factors driving this increase, including the rise in the number of patients cared for and in the complexity of their care; and the general rise in litigation across a number of sectors including the NHS, driven in part by ‘no win, no fee’ agreements. It is anticipated that the effect of the latter is likely to diminish as a result of the Government’s Legal Aid Sentencing and Punishment of Offenders Act of 2012.</p><p> </p><p>The Department believes the best way to reduce negligence claims is to improve patient care and safety. In March 2014, the Secretary of State for Health issued a call to action to make the NHS the safest healthcare system in the world and achieve a three-year goal to halve avoidable harm and save 6,000 lives. The Sign up to Safety campaign embodies the ambition of the NHS to build a culture of safety, bringing together individuals and organisations with a contribution to make towards the patient safety goal. Elements of this campaign will focus on a reduction in avoidable harm that can lead to compensation claims. Organisations that sign up are setting out what they will do to strengthen patient safety, including a safety improvement plan which shows how their organisation intends to save lives and reduce harm for patients over the next three years. The NHS Litigation Authority, which already provides a “safety and learning service” to trusts<strong>,</strong> will support those organisations which have patient safety improvement plans that show a likely reduction in their higher volume, higher value claims.</p><p> </p> answering member printed Earl Howe question first answered 04/12/2014 16:04:05 question first ministerially corrected 13/01/2015 14:37:59 answering member 2000 label Biography information for Earl Howe previous answer version 31769 answering member printed Earl Howe answering member 2000 label Biography information for Earl Howe
	tabling member	4196 label Biography information for Lord Sharkey

61086

	registered interest
	date	10/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many training places for general practice were (a) commissioned and (b) filled in each of the last five years.
	tabling member constituency	Copeland
	tabling member printed	Mr Jamie Reed
	uin	200007
	answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>The Department set up Health Education England (HEE) to deliver a better health and healthcare workforce for England. HEE is responsible for ensuring a secure workforce supply for the future balancing need against demand, taking into account factors such as the age profile of the existing workforce, the impact of technology, and new drugs.</p><p> </p><p>The Department has recognised the need to increase the general practitioner (GP) workforce and between September 2010 and September 2013, the number of full time equivalent GPs has risen by 1,051. Additionally, the Department has included in the HEE mandate a requirement that “HEE will ensure that 50% of trainees completing foundation level training enter GP training programmes by 2016”.</p><p> </p><p>Further work is being undertaken by HEE to improve applications and fill rate in to GP training to support the mandate target of 3,250 appointments into GP training by 2016 in England. This includes a review of the GP recruitment process, developing a pre-GP year to give exposure to prospective GP applicants of the specialty and careers advice for foundation doctors and medical students.</p><p> </p><p>In recognition of the contribution the GP workforce makes in the NHS, HEE will also undertake additional work on GP recruitment and retention, return to practice and reducing attrition rates, all of which will play a part in increasing the GP workforce.</p><p> </p><p>The following table indicates the number of posts commissioned and filled and the fill rate for GP training in England for the last five years. The numbers of posts have been increased for 2014 to 2,946 to support the government’s mandate requirement for HEE to increase GP training.</p><p> </p><p> </p><p> </p><table><tbody><tr><td> </td><td><p>Posts Commissioned</p></td><td><p>Posts Filled</p></td><td><p>% Filled</p></td></tr><tr><td><p>2010</p></td><td><p>2,732</p></td><td><p>2,800</p></td><td><p>102.49%</p></td></tr><tr><td><p>2011</p></td><td><p>2,672</p></td><td><p>2,658</p></td><td><p>99.48%</p></td></tr><tr><td><p>2012</p></td><td><p>2,687</p></td><td><p>2,669</p></td><td><p>99.33%</p></td></tr><tr><td><p>2013</p></td><td><p>2,761</p></td><td><p>2,738</p></td><td><p>99.17%</p></td></tr><tr><td><p>2014</p></td><td><p><del class="ministerial">2,946</del> <ins class="ministerial">3,043</ins></p></td><td><p>2,630</p></td><td><p>89.27%</p></td></tr></tbody></table><p> </p><p><em>Source</em>: HEE data</p><p> </p><p>Deferment resulting from factors such as maternity leave can cause a higher than 100% fill rate in some years.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 16/06/2014 16:44:34 question first ministerially corrected 14/10/2014 10:52:22 answering member 3932 label Biography information for Dr Dan Poulter previous answer version 1687 answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	1503 label Biography information for Mr Jamie Reed

61553

	registered interest
	date	12/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Learning Disability: Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to ensure that people with learning disabilities are not excluded from NHS England's five-year strategic plan for National Health Service commissioners to improve quality of and access to health care, outlined in Everyone Counts: Planning for Patients 2014/15–2018/19.
	tabling member printed	Baroness Hollins
	uin	HL322
	answer	answer is ministerial correction date of answer 26/06/2014 answer text <p>The Government's Mandate to NHS England, sets out our ambitions for the health service, which include an objective that NHS England ensures clinical commissioning groups work with local authorities to ensure that vulnerable people, particularly those with learning disabilities and autism, receive safe, appropriate, high quality care. NHS England sets out how it will achieve the objectives in the Mandate in its 2014-15 – 2016-17 business plan. The Government will hold NHS England to account for its achievement.</p><p> </p><p><em>Everyone Counts: Planning for Patients 2014/15 to 2018/19</em>sets out a framework within which commissioners will need to work with providers and partners in local government to develop five year plans to secure the continuity of sustainable high quality care for all. Building on <em>Everyone Counts</em>, NHS England is beginning a programme of work to consider how to improve quality of and access to health care for people with learning disabilities. Within the framework there is specific reference to <em>Transforming Care: A national response to Winterbourne View Hospital. </em>This is a non-negotiable item that NHS England expects to be part of every relationship between commissioners and providers. As part of this, clinical commissioning groups, local authorities and specialised commissioners should work together to implement the core specification which describes the core principles that must be present in all education, health and social care services for children, young people, adults and older people with learning disabilities and/or autism who either display, or are at risk of displaying, behaviour that challenges.</p><p> </p><p>NHS England is committed to work to reduce premature mortality amongst people with learning disability, including actions in response to the Confidential Inquiry into Premature Deaths of People with Learning Disabilities.</p><p> </p> answering member printed Earl Howe question first answered 26/06/2014 14:01:36 question first ministerially corrected 26/06/2014 15:34:49 answering member 2000 label Biography information for Earl Howe previous answer version 6304 answering member printed Earl Baldwin of Bewdley answering member 3446
	tabling member	4190 label Biography information for Baroness Hollins

63270

	registered interest
	date	23/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	GP Surgeries: Repairs and Maintenance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many general practitioner practices were (a) refurbished and (b) replaced in each of the last 10 years.
	tabling member constituency	Copeland
	tabling member printed	Mr Jamie Reed
	uin	201710
	answer	answer is ministerial correction date of answer 26/06/2014 answer text <p>Prior to April 2013, granting funding for the refurbishment and replacement of general practitioner premises was the responsibility of primary care trusts (PCTs). Information pertaining to this period is not held centrally and could only be obtained at disproportionate cost.</p><p> </p><p>Responsibility for funding general practice premises development has now been transferred to NHS England.</p><p> </p><p>Between 1 April 2013 and 1 April 2014, more than 100 business cases for premises development were approved by NHS England. NHS England <ins class="ministerial">will be publishing </ins><del class="ministerial">has now published</del> Principles of Good Practice <ins class="ministerial">later in the autumn. This </ins> <del class="ministerial">that</del> set<ins class="ministerial">s</ins> out how <del class="ministerial">area</del> teams should review and prioritise business case proposals, and since 1 April 2014 a further 46 business cases have been approved.</p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 26/06/2014 14:49:17 question first ministerially corrected 11/09/2014 13:48:27 answering member 1439 label Biography information for Norman Lamb previous answer version 6377 answering member constituency North Norfolk answering member printed Norman Lamb answering member 1439 label Biography information for Norman Lamb
	tabling member	1503 label Biography information for Mr Jamie Reed

64342

	registered interest
	date	26/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Knee Replacements
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many NHS knee replacement operations were carried out in England, by region, in the last three years.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	202780
	answer	answer is ministerial correction date of answer 03/07/2014 answer text <p>The attached table shows how many knee replacement operations were carried out in England, by region, in the last three years.</p><p> </p><p>The following table shows how many knee replacement revisions were carried out by the National Health Service in England in the last three years. Information relating to how long the average time interval was between total knee replacement and subsequent revision procedures is not held centrally.</p><table><tbody><tr><td><p>Year</p></td><td><p>Region</p></td><td><p>Full Knee Replacement</p></td><td><p>Only one bone in the knee joint is replaced</p></td></tr><tr><td><p>2010-11</p></td><td><p>North East</p></td><td><p>456</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>North West</p></td><td><p>825</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>Yorkshire And The Humber</p></td><td><p>759</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>East Midlands</p></td><td><p>551</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>West Midlands</p></td><td><p>751</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>East Of England</p></td><td><p>733</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>London</p></td><td><p>738</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South East Coast</p></td><td><p>673</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South Central</p></td><td><p>670</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South West</p></td><td><p>868</p></td><td><p>7</p></td></tr><tr><td> </td><td><p>England Total</p></td><td><p>7,024</p></td><td><p>25</p></td></tr><tr><td><p>2011-12</p></td><td><p>North East</p></td><td><p>422</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>North West</p></td><td><p>704</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>Yorkshire And The Humber</p></td><td><p>751</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>East Midlands</p></td><td><p>547</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>West Midlands</p></td><td><p>728</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>East Of England</p></td><td><p>612</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>London</p></td><td><p>747</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South East Coast</p></td><td><p>613</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South Central</p></td><td><p>576</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South West</p></td><td><p>839</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>England Total</p></td><td><p>6,539</p></td><td><p>14</p></td></tr><tr><td><p>2012-13</p></td><td><p>North East</p></td><td><p>396</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>North West</p></td><td><p>759</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>Yorkshire And The Humber</p></td><td><p>677</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>East Midlands</p></td><td><p>572</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>West Midlands</p></td><td><p>713</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>East Of England</p></td><td><p>596</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>London</p></td><td><p>768</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South East Coast</p></td><td><p>584</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South Central</p></td><td><p>545</p></td><td><p>*</p></td></tr><tr><td> </td><td><p>South West</p></td><td><p>915</p></td><td><p>8</p></td></tr><tr><td> </td><td><p>England Total</p></td><td><p>6,525</p></td><td><p>18</p></td></tr></tbody></table><p><em>Notes: </em></p><p>1. Finished Consultant Episode (FCE): Both tables show FCEs. An FCE is a continuous period of admitted patient care under one consultant within one healthcare provider. FCEs are counted against the year in which they end. The figures do not represent the number of different patients, as a person.</p><p>2. The data should not be described as a count of people as the same person may have been admitted on one or more occasion.</p><p>3. †Providers that are not based in England have been removed, and therefore the national totals may not be equal to the sum of the regional totals.</p><p>4. To protect patient confidentiality, figures between 1 and 5 have been replaced with “*” (an asterisk). Where it was still possible to identify figures from the total, additional figures have been replaced with &quot;*”.</p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 03/07/2014 14:46:03 question first ministerially corrected 28/10/2014 09:31:52 answering member 3918 label Biography information for Jane Ellison attachment 1 file name PQ202780_PQ202778 - Amended Table.docx title Table previous answer version 7888 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison attachment 1 file name PQ202780_PQ202778 - Table.docx title Table
	tabling member	3985 label Biography information for Robert Halfon

90125

	registered interest
	date	01/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what payments have been received in the 2014-15 financial year by GPs for the delivery of vaccines through each routine immunisation programme, broken down by (a) item-of-service payment, (b) administration fee, (c) reimbursement cost, (d) Quality and Outcomes Framework reward and (e) Directed Enhanced Service payment; and if he will make a statement.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	207552
	answer	answer is ministerial correction date of answer 08/09/2014 answer text <p>Data for the current financial year <ins class="ministerial">are </ins><del class="ministerial"> is</del> not yet available. Financial data on overall spend of vaccination and immunisation programmes <ins class="ministerial">in general practice are </ins><del class="ministerial">is</del> published by the Health and Social Care Information Centre (HSCIC) <del class="ministerial">once it has undergone routine checks and audits as set by the National Audit Office</del>.</p><p> </p><p> </p><p> </p><p>HSCIC <del class="ministerial">will</del> publish<ins class="ministerial">ed</ins> the data for 2013-14 on <ins class="ministerial">19 </ins><del class="ministerial">22</del> September 2014.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/09/2014 14:40:24 question first ministerially corrected 28/10/2014 11:10:30 answering member 3918 label Biography information for Jane Ellison previous answer version 18802 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
	tabling member	104 label Biography information for Crispin Blunt

91293

	registered interest
	date	09/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 5 September 2014, Official Report, column 382W, on General Practitioners, for what reason the figure for financial year 2009-10 (the figure as at September 2009) was not included in that answer.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	208788
	answer	answer is ministerial correction date of answer 14/10/2014 answer text <p>The omission of the figure for financial year 2009-10 (the figure as at September 2009) in the Answer of 5 September 2014, Official Report, column 382W, on general practitioners (GPs), was an error on our part. The September 2010 figures provided instead were accurate and there was no intention to mislead.</p><p> </p><p> </p><p> </p><p>The numbers of full-time equivalent (FTE) GPs, excluding retainers and registrars, and including retainers but excluding registrars, working in the NHS in England as at September 2009, 2010 and 2013 are shown in the following table. The number of FTE GPs has increased by 1,051 between 2010 and 2013.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 14/10/2014 14:35:00 question first ministerially corrected 15/10/2014 13:58:12 answering member 3932 label Biography information for Dr Dan Poulter attachment 1 file name PQ208788 GP numbers 2009-13.xlsx title GP Numbers 2009, 2010 and 2013 previous answer version 21782 answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	4036 label Biography information for Luciana Berger

92595

	registered interest
	date	10/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Records: Databases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the potential benefits to the NHS of increasing the extent to which patient-level data is shared between organisations; and if he will make a statement.
	tabling member constituency	Sutton and Cheam
	tabling member printed	Paul Burstow
	uin	209873
	answer	answer is ministerial correction date of answer 17/10/2014 answer text <p>Effective sharing of patient information between organisations as part of a person’s direct care has enormous potential to improve patient care, services and treatments and can only be done effectively if patients are given a say over how their personal information is used.</p><p> </p><p> </p><p> </p><p>The sharing of patient information, whilst protecting confidentiality, ensures the highest standards of care and clinical safety are consistently met throughout the National Health Service and where standards drop, allowing prompt action to be taken. It also helps to understand what happens to people, especially those with long term conditions, who are cared for away from hospital, and to ensure their needs are met and provides vital information needed to assist and support research into new medicines, and the better treatment of disease.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 17/10/2014 08:53:07 question first ministerially corrected 17/10/2014 09:05:53 answering member 3932 label Biography information for Dr Dan Poulter previous answer version 22453 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	204 label Biography information for Paul Burstow

92598

	registered interest
	date	10/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Records: Databases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent progress has been made on the care.data project; and if he will make a statement.
	tabling member constituency	Sutton and Cheam
	tabling member printed	Paul Burstow
	uin	209877
	answer	answer is ministerial correction date of answer 17/10/2014 answer text <p>NHS England made an announcement on the progress of the care.data project on October 7.</p><p> </p><p> </p><p> </p><p>Further details can be found at:</p><p> </p><p> </p><p> </p><p>http://www.england.nhs.uk/2014/10/07/ccgs-care-data-programme/</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 17/10/2014 08:57:51 question first ministerially corrected 17/10/2014 09:05:37 answering member 3932 label Biography information for Dr Dan Poulter previous answer version 22454 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	204 label Biography information for Paul Burstow

92843

	registered interest
	date	13/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many GPs working in the NHS aged (a) 25 to 35, (b) 35 to 45, (c) 45 to 55 and (d) 55 to 65 years old are (i) male and (ii) female.
	tabling member constituency	Vale of Clwyd
	tabling member printed	Chris Ruane
	uin	210052
	answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>The Health and Social Care Information Centre General and Personal Medical Services workforce census shows the number of general practitioners (GPs) by age band and gender working in the NHS in England as at 30 September each year.</p><p> </p><p> </p><p> </p><p>The attached table shows the number of GPs (excluding registrars and retainers) but including GP providers (partners) and GP others (salaried) by age band and gender as at 30 September 2013 working in the NHS in England.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 20/10/2014 16:41:38 question first ministerially corrected 20/10/2014 16:54:36 answering member 3932 label Biography information for Dr Dan Poulter attachment 1 file name PQ210052 GPs by age band.xlsx title GPs by Age Band Sept 2013 previous answer version 23112 answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	534 label Biography information for Chris Ruane

100020

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners: Standards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what progress has been made on improving access to GPs.
	tabling member constituency	Weaver Vale
	tabling member printed	Graham Evans
	uin	905556
	answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>The Prime Minister’s £50 million Challenge Fund is currently improving general practitioner access for over two million patients across England. This includes offering evening and weekend appointments, as well as better use of technology, such as telehealth, to look after patients. By January, 7.5 million patients will be covered.</p><p> </p><p> </p><p> </p><p>And, we have recently announced another £100 million of funding for next year to improve access for even more patients.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 21/10/2014 15:48:51 answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	4081 label Biography information for Lord Evans of Rainow

100021

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Home Care Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will bring forward proposals to facilitate the portability of home-based care packages between local authorities in different countries in the UK.
	tabling member constituency	Edinburgh East
	tabling member printed	Sheila Gilmore
	uin	905560
	answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>Adults with care and support needs should be able to move between countries within the United Kingdom knowing that their care will continue during the move.</p><p> </p><p> </p><p> </p><p>As the care and support systems in the four countries are different, we are developing principles with the Devolved Administrations to ensure continuity of care for people moving.</p><p> </p><p>These should be published in November.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 21/10/2014 15:45:44 answering member 1439 label Biography information for Norman Lamb
	tabling member	3965 label Biography information for Sheila Gilmore

100022

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patient Choice Schemes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to promote patient choice.
	tabling member constituency	Stroud
	tabling member printed	Neil Carmichael
	uin	905559
	answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/10/2014 16:00:56 answering member 4020 label Biography information for George Freeman
	tabling member	4104 label Biography information for Neil Carmichael

100023

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to increase early identification of ovarian cancer.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	905561
	answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>We are investing £450 million in earlier diagnosis of cancer, including improving direct general practitioner access to non-obstetric ultrasound to support earlier diagnosis of ovarian cancer.</p><p> </p><p> </p><p> </p><p>Public Health England ran a regional Be Clear on Cancer campaign early in 2014 to raise awareness of the symptoms of ovarian cancer. The findings of the pilot will be evaluated in 2015, and this evidence would inform any decision to move from a regional to national campaign.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/10/2014 15:46:38 answering member 3918 label Biography information for Jane Ellison
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

100024

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Community Health Services: Devon
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will increase funding from the Better Care Fund to improve the transition of community services in Devon.
	tabling member constituency	North Devon
	tabling member printed	Sir Nick Harvey
	uin	905558
	answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>The Better Care Fund is a pooled budget of £3.8 billion to be spent on integrating Health and Social care. Local areas will decide how best to use their funding to transform the provision of services to their communities, both improving outcomes for people, and driving efficiencies.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 21/10/2014 15:44:45 answering member 1439 label Biography information for Norman Lamb
	tabling member	231 label Biography information for Sir Nick Harvey

100031

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Liver Diseases
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they are taking to reverse the rise in liver deaths in England between 2001 and 2012 shown by Public Health England’s report <i>Liver Disease Profiles</i>.
	tabling member printed	Lord Avebury
	uin	HL2237
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>Public Health England (PHE) has a comprehensive range of action aimed at reducing the incidence and mortality from liver disease. It monitors the incidence, mortality and outcomes of treatment for liver disease and the risk factors: alcohol obesity and Hepatitis B and C. PHE has a wide range of action to tackle unhealthy alcohol consumption, obesity and viral hepatitis through strengthening local action, promoting healthy choices, and giving appropriate information to support healthier lives. <br> <br> In response to the All Party Parliamentary Hepatology Group report PHE has committed to producing a PHE Liver Disease Framework. This will focus on public health action to tackle risk factors for liver disease and inequalities in relation to liver disease. Work has already begun to bring together expertise within PHE on the major risk factors for liver disease (alcohol, hepatitis B and C and obesity), data on liver disease and its risk factors and on death and dying from liver disease. Many of the actions to tackle the major risk factors require a coordinated approach between PHE and NHS England.</p><p> </p><p><br> NHS England is responsible for delivering improvements in outcomes against the NHS Mandate and in line with the NHS Outcomes Framework. NHS England are adopting a broad strategy for delivering improvements in relation to premature mortality, working with commissioners and PHE to support clinical commissioning groups in understanding where local challenges lie and in identifying the evidence in relation to the priorities for reducing mortality at a national level.</p><p> </p> answering member printed Earl Howe question first answered 03/11/2014 11:52:44 answering member 2000 label Biography information for Earl Howe
	tabling member	1665 label Biography information for Lord Avebury

100035

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Reorganisation
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the cost to date of the reorganisation of the National Health Service as a result of the reforms in the Health and Social Care Act 2012.
	tabling member printed	Baroness McDonagh
	uin	HL2241
	answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>I announced in my Written Ministerial Statement of 23 July 2014, columns WS135-136, that the costs of implementing policies in the Health and Social Care Act incurred to 31 March 2014 were £1,316 million. This is the latest available figure.</p><p> </p><p> </p><p> </p><p>These costs have been more than covered by the savings arising from the Health and Social Care Act, which up to 31 March 2014, were approximately £4.9 billion.</p><p> </p> answering member printed Earl Howe question first answered 04/11/2014 12:33:57 answering member 2000 label Biography information for Earl Howe
	tabling member	3701 label Biography information for Baroness McDonagh